CLIA Validation of a New High Performance HPV ctDNA Assay Covering Multiple High Risk HPV Types
C. Hochfelder,H. Walline,C. Bhambhani,C. Brummel,E. Sandford,R. Akhdar,K. Casper,S.B. Chinn,M.E. Heft-Neal,K. Malloy,J.L. Shah,A. Shuman,M. Spector,C.L. Stucken,F. Worden,M.E. Prince,M.L. Mierzwa,P.L. Swiecicki,M. Tewari,C. Brenner
DOI: https://doi.org/10.1016/j.ijrobp.2024.01.139
IF: 8.013
2024-04-01
International Journal of Radiation Oncology*Biology*Physics
Abstract:Purpose/Objective(s) To develop and CLIA validate a droplet digital PCR (ddPCR) assay capable of enhancing the detection of multiple high-risk types of human papillomavirus (hrHPV) circulating tumor DNA (ctDNA) in plasma from patients with HPV-associated oropharyngeal squamous cell carcinoma (HPV+ OPSCC). Materials/Methods We advanced our previously developed HPV16 probes, and newly developed hrHPV probes designed to detect HPV-18, HPV-31, HPV-33, HPV-35 and HPV-39 (total 26 primers and 13 probes) as a new high-performance assay for validation in our CLIA certified laboratory using Clinical and Laboratory Standards Institute (CLSI) guidelines. Analytical control and plasma samples from HPV+ OPSCC patients were used to characterize and validate the performance as a lab developed test (LDT). Results The assay demonstrated analytical accuracy and precision during in depth evaluation consistent with requirements for clinical use. For HPV16, the assay had a limit of the blank (LOB) of 0 copies/µL, a limit of detection (LOD) of 0.53 copies/µL, and a limit of quantification (LOQ) ranging from 1.29 - 4.36 copies/µL. For detection of other hrHPV types, the assay had a LOB of 0 copies/µL, a LOD of 0.77 copies/µL, and a LOQ ranging from 1.72 – 14.0 copies/µL. Regression of the observed copy number versus measured concentration of HPV DNA, and the observed versus expected copy number had excellent correlation in the linear range of the assays (R2 = 0.99 for each). For HPV16, the assay had a linear range from 0.53 to 9384 copies/µL. For other hrHPV types, the assay had a linear range from 0.77 to 6000 copies/µL. Above the linear range of each assay, the analyte was detected resulting in a positive test, but recovery was <90%. Testing of blanks following known positive samples did not find any substantial carry over. Testing of analytes over a 96-hour period showed appropriate stability of the analyte (both primary and processed) and assay over time. Cross-reactivity was assessed using each assay (alone and in combination) to evaluate contrived samples of HPV16, HPV18, HPV31, HPV33, HPV35, and HPV39 (individually and in combination) and found that there was no substantial cross-reactivity between the assays or HPV types, confirming the high specificity of the assay for HPV type. Conclusion These results confirm this assay has both high analytical sensitivity and specificity for detection of multiple hrHPV types and is capable of detecting low levels of HPV ctDNA from clinical plasma samples.
oncology,radiology, nuclear medicine & medical imaging